(Q40463597)

20 September 2017

1 reference

title

Novel antithrombotic drugs in development. (English)

1 reference

20 September 2017

M Verstraete

1

1 reference

20 September 2017

P Zoldhelyi

series ordinal

2

1 reference

20 September 2017

publication date

1 June 1995

1 reference

20 September 2017

1 reference

20 September 2017

volume

49

1 reference

20 September 2017

issue

6

1 reference

20 September 2017

page(s)

856-884

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199549060-00002

20 September 2017

exact match

0 references

cites work

Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae

1 reference

12 December 2020

Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans

1 reference

12 December 2020

Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis

1 reference

12 December 2020

Structure of the hirugen and hirulog 1 complexes of alpha-thrombin

1 reference

12 December 2020

Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons

1 reference

12 December 2020

Low doses of activated protein C delay arterial thrombosis in rats

1 reference

12 December 2020

Cloning and expression of the cDNA for human antithrom, bin III

1 reference

12 December 2020

Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis

1 reference

12 December 2020

STUDIES IN EXPERIMENTAL EXTRACORPOREAL THROMBOSIS : III. EFFECTS OF CERTAIN ANTICOAGULANTS (HEPARIN AND HIRUDIN) ON EXTRACORPOREAL THROMBOSIS AND ON THE MECHANISM OF THROMBUS FORMATION.

1 reference

12 December 2020

The biochemical pharmacology of thromboxane synthase inhibition in man.

1 reference

12 December 2020

Effect of some mucopolysaccharides on activated factor X

1 reference

12 December 2020

Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system

1 reference

12 December 2020

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

1 reference

12 December 2020

Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor

1 reference

12 December 2020

The action of a synthetic pentasaccharide on thrombin generation in whole plasma

1 reference

12 December 2020

Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis

1 reference

12 December 2020

Critical evaluation of the in vivo selectivity between hypotensive and platelet antiaggregating actions of iloprost and prostacyclin in beagle dogs.

1 reference

12 December 2020

Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement

1 reference

12 December 2020

Pharmacology of ticlopidine: a review

1 reference

12 December 2020

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon

1 reference

12 December 2020

Antithrombotic and thrombolytic activity of sulodexide in rats

1 reference

12 December 2020

Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects

1 reference

12 December 2020

Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon

1 reference

12 December 2020

Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group

1 reference

12 December 2020

Hirudins: antithrombin anticoagulants

1 reference

12 December 2020

Orgaran (Org 10172): its pharmacological profile in experimental models

1 reference

12 December 2020

Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation

1 reference

12 December 2020

Agkistrodon piscivorus piscivorus platelet aggregation inhibitor: a potent inhibitor of platelet activation

1 reference

12 December 2020

"In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets

1 reference

12 December 2020

Clopidogrel--a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions

1 reference

12 December 2020

Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli.

1 reference

12 December 2020

Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).

1 reference

12 December 2020

Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen

1 reference

12 December 2020

Modulation of arachidonate metabolite generation in human blood by oral defibrotide

1 reference

12 December 2020

Factor VII and extrinsic pathway inhibitor in acute coronary disease

1 reference

12 December 2020

Characterization of recombinant human antithrombin III synthesized in Chinese hamster ovary cells

1 reference

12 December 2020

Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin

1 reference

12 December 2020

Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri

1 reference

12 December 2020

The antithrombotic efficacy of dextran.

1 reference

12 December 2020

Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide

1 reference

12 December 2020

Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin.

1 reference

12 December 2020

G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.

1 reference

12 December 2020

Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin

1 reference

12 December 2020

Primary structure of human placental anticoagulant protein

1 reference

12 December 2020

Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid

1 reference

12 December 2020

Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate

1 reference

12 December 2020

Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats

1 reference

12 December 2020

Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex

1 reference

12 December 2020

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

12 December 2020

The basic pharmacology of ticlopidine and clopidogrel

1 reference

12 December 2020

R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro

1 reference

12 December 2020

Sulodexide oral administration influences blood viscosity and fibrinolysis

1 reference

12 December 2020

Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial

1 reference

12 December 2020

Purification and characterization of a novel protein from bovine aorta that inhibits coagulation. Inhibition of the phospholipid-dependent factor-Xa-catalyzed prothrombin activation, through a high-affinity binding of the anticoagulant to the phosph

1 reference

12 December 2020

BM 13.177, A SELECTIVE BLOCKER OF PLATELET AND VESSEL WALL THROMBOXANE RECEPTORS, IS ACTIVE IN MAN

1 reference

12 December 2020

Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries

1 reference

12 December 2020

Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistasin following subcutaneous administration in the rhesus monkey

1 reference

12 December 2020

Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin

1 reference

12 December 2020

Antiplatelet Therapy in the Prevention of Stroke???

1 reference

12 December 2020

Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group

1 reference

12 December 2020

Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor

1 reference

12 December 2020

Cloning and expression of cDNA for human vascular anticoagulant, a Ca2+-dependent phospholipid-binding protein

1 reference

12 December 2020

Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide

1 reference

12 December 2020

Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine prepa

1 reference

12 December 2020

Antithrombotic effects of recombinant human soluble thrombomodulin in a rat model of vascular shunt thrombosis

1 reference

12 December 2020

SC-54684A: an orally active inhibitor of platelet aggregation

1 reference

12 December 2020

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

12 December 2020

Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor

1 reference

12 December 2020

Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial

1 reference

12 December 2020

Inhibition of platelet hemostatic plug formation by trigramin, a novel RGD-peptide

1 reference

12 December 2020

Studies of chemical and biologic properties of a fraction of sulodexide, a heparin-like glycosaminoglycan

1 reference

12 December 2020

Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets

1 reference

12 December 2020

Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP

1 reference

12 December 2020

Presence and function of chondroitin-4-sulfate on recombinant human soluble thrombomodulin

1 reference

12 December 2020

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

1 reference

12 December 2020

The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man.

1 reference

12 December 2020

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

1 reference

12 December 2020

Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial

1 reference

12 December 2020

Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition

1 reference

12 December 2020

Pharmacokinetics and anticoagulant effect of hirudin in man.

1 reference

12 December 2020

Characterization of a functional thrombin receptor. Issues and opportunities

1 reference

12 December 2020

A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex

1 reference

12 December 2020

Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase

1 reference

12 December 2020

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

1 reference

12 December 2020

Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke

1 reference

12 December 2020

Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the .gamma. chain

1 reference

12 December 2020

The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity

1 reference

12 December 2020

Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.

1 reference

12 December 2020

Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders

1 reference

12 December 2020

Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group

1 reference

12 December 2020

Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers

1 reference

12 December 2020

MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man

1 reference

12 December 2020

Suitability of low-molecular-weight heparin(oid)s and a pentasaccharide for an in vitro human thrombosis model.

1 reference

12 December 2020

Antithrombin III: biodistribution in healthy volunteers.

1 reference

12 December 2020

Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial

1 reference

12 December 2020

Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors

1 reference

12 December 2020

1 reference

12 December 2020

Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders

1 reference

12 December 2020

Substitution of antithrombin III in shock and DIC: a randomized study

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.

1 reference

12 December 2020

Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters

1 reference

12 December 2020

DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.

1 reference

12 December 2020

Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin

1 reference

12 December 2020

Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate

1 reference

12 December 2020

Antithrombotic activity of a glycosaminoglycan (sulodexide) in rats

1 reference

12 December 2020

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

12 December 2020

Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells. Effect of glycosylation differences on heparin binding and structure.

1 reference

12 December 2020

Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model

1 reference

12 December 2020

Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine

1 reference

12 December 2020

Treatment of congenital antithrombin III deficiency with concentrates

1 reference

12 December 2020

Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age.

1 reference

12 December 2020

Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries

1 reference

12 December 2020

A database of recombinant wild-type and mutant serpins

1 reference

12 December 2020

Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in nonhuman primates

1 reference

12 December 2020

Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.

1 reference

12 December 2020

Defibrotide stimulates expression of thrombomodulin in human endothelial cells

1 reference

12 December 2020

Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion

1 reference

12 December 2020

Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors

1 reference

12 December 2020

Pharmacologic profiling of defibrotide in experimental models.

1 reference

12 December 2020

"Mirror image" antagonists of thrombin-induced platelet activation based on thrombin receptor structure

1 reference

12 December 2020

Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor

1 reference

12 December 2020

Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation

1 reference

12 December 2020

Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.

1 reference

12 December 2020

Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia

1 reference

12 December 2020

Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty

1 reference

12 December 2020

Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction

1 reference

12 December 2020

The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action

1 reference

12 December 2020

Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C

1 reference

12 December 2020

Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins

1 reference

12 December 2020

Transmission of conformational change from the heparin binding site to the reactive center of antithrombin

1 reference

12 December 2020

Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis

1 reference

12 December 2020

Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty

1 reference

12 December 2020

Inhibition of microarterial thrombosis by activated protein C in a rabbit model.

1 reference

12 December 2020

Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma

1 reference

12 December 2020

Purification and characterization of inhibitors of blood coagulation factor Xa from hematophagous organisms

1 reference

12 December 2020

Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.

1 reference

12 December 2020

Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: Possible explanation of mechanism of inhibition of platelet function

1 reference

12 December 2020

On the mechanism of the prolonged action in man of GR32191, a thromboxane receptor antagonist

1 reference

12 December 2020

Hirudisins. Hirudin-derived thrombin inhibitors with disintegrin activity

1 reference

12 December 2020

Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism

1 reference

12 December 2020

Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

12 December 2020

Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme

1 reference

12 December 2020

Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis

1 reference

12 December 2020

Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model

1 reference

12 December 2020

Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates

1 reference

12 December 2020

Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa

1 reference

12 December 2020

Thrombomodulin blocks the ability of thrombin to activate platelets

1 reference

12 December 2020

Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice

1 reference

12 December 2020

Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque

1 reference

12 December 2020

Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains

1 reference

12 December 2020

Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis

1 reference

12 December 2020

Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator

1 reference

12 December 2020

Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications

1 reference

12 December 2020

AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2.

1 reference

12 December 2020

Structure and expression of cDNA for an inhibitor of blood coagulation isolated from human placenta: a new lipocortin-like protein

1 reference

12 December 2020

Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers

1 reference

12 December 2020

Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor

1 reference

12 December 2020

Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures

1 reference

12 December 2020

In vivo antithrombotic effect of triflavin, an Arg-Gly-Asp containing peptide on platelet plug formation in mesenteric microvessels of mice

1 reference

12 December 2020

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation

1 reference

12 December 2020

1 reference

12 December 2020

Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord

1 reference

12 December 2020

IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction

1 reference

12 December 2020

Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons

1 reference

12 December 2020

Low molecular weight heparin

1 reference

12 December 2020

Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease

1 reference

12 December 2020

Oral anticoagulant drugs

1 reference

12 December 2020

The protective effect of autoprothrombin II - anticoagulant on experimental DIC in animals

1 reference

12 December 2020

Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries

1 reference

12 December 2020

Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation

1 reference

12 December 2020

Low molecular weight heparin

1 reference

12 December 2020

Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats

1 reference

12 December 2020

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

12 December 2020

Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity

1 reference

12 December 2020

Intermediate reactions in the coagulation of blood with tissue thromboplastin; convertin, accelerin, prothrombinase

1 reference

12 December 2020

The selective inhibition of thrombin by peptides of boroarginine

1 reference

12 December 2020

Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid

1 reference

12 December 2020

Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states

1 reference

12 December 2020

Expression of human antithrombin III in Saccharomyces cerevisiae and Schizosaccharomyces pombe

1 reference

12 December 2020

Importance of factor Xa in determining the procoagulant activity of whole-blood clots

1 reference

12 December 2020

[Isolation and chemical characterization of hirudin]

1 reference

12 December 2020

Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between Org 10172 and dextran 70

1 reference

12 December 2020

Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A

1 reference

12 December 2020

Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation

1 reference

12 December 2020

Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin

1 reference

12 December 2020

A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.

1 reference

12 December 2020

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

1 reference

12 December 2020

Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor

1 reference

12 December 2020

Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man

1 reference

12 December 2020

Reduction in thrombus formation by PG-1 F(ab')2, an anti-guinea pig platelet glycoprotein Ib monoclonal antibody

1 reference

12 December 2020

Antithrombotic drugs in pelvic surgery

1 reference

12 December 2020

The roles of protein C and thrombomodulin in the regulation of blood coagulation

1 reference

12 December 2020

Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial

1 reference

12 December 2020

Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition

1 reference

12 December 2020

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

12 December 2020

10.2165/00003495-199549060-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1011280093

0 references

1 reference